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Tumor necrosis factor (TNF) is a protein synthesized and secreted by mono-
nuclear phagocytes in response to stimulation with bacterial endotoxin and other
agents . Originally TNF was defined functionally as the factor in postendotoxin
serum from Propionibacterium acnes-treated mice that mediated hemorrhagic
necrosis of established fibrosarcomas in recipient mice (1) . More recently, it has
been established that TNF, and cachectin, the molecule responsible for the toxic
symptoms of endotoxin, are one and the same molecule (2, 3) . The genes for
human (4-7)and mouse (7, 8) TNFhave been clonedandexpressed in Escherichia
coli . Consequently, adequate quantities of pure humanand mouse rTNF are now
available for study.
For the most part, the antitumor function ofrTNF has been studied in terms
of its cytotoxic activity for neoplastic cells in vitro. Such studies are an extension,
therefore, of those originally performed (9) with TNF-containing postendotoxin
serum (TNS)' from P . acnes-treated mice . TNS was shown to be capable of
killing certain neoplastic cells in vitro, as well as causing hemorrhagic necrosis of
established tumors in vivo. Indeed, it hasbeen often assumed, since these original
findings, that the in vivo therapeutic action of TNF is based on its ability to
directly kill cells of the tumor . However, the evidence that TNF is therapeutic
in vivo is not particularly convincing in that it is not based on the ability ofTNF
to cause tumor regression, but on its ability to cause hemorrhagic necrosis of the
centers of established tumors . In other words, treatment with TNF rarely results
in complete regression of the ring of living tumor tissue that survives central
hemorrhagic necrosis .
The same shortcoming applies to therapy with bacterial endotoxin, which has
been known for many years to be capable ofcausing central hemorrhagic necrosis
of most tumors, but complete regression of only some (10) . The possible reason
for the limited therapeutic effect of endotoxin was supplied by Parr et al . (11),
who demonstrated that only immunogenic tumors are susceptible to endotoxin-
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induced regression, and that immunogenic tumors fail to undergo complete
regression ifthey are growing in immunosuppressed mice. These findings were
essentially confirmed by others (12, 13), who postulated that endotoxin-induced
tumor regression, as opposed tohemorrhagic necrosis, dependson thepossession
by the host ofan underlying mechanism of antitumor immunity. It was demon-
strated more recently (14) that endotoxin-inducedregression ofan immunogenic
sarcoma depends on the preceding generation by the host of a subtherapeutic
number of tumor-sensitized L3T4'' T cells. Given the belief that TNF is the
mediator of endotoxin-induced tumor regression, it might be expected that
TNF-induced tumor regression is also immunologically dependent.
The purpose of this paper is to present results in keeping with the view that
the therapeutic action ofTNF against an established immunogenic sarcoma does
not depend on the ability of TNF to directly destroy cells ofthis tumor in vivo,
but on its ability to directly or indirectly destroy the tumor's vasculature. In this
way destruction ofmost ofthe center of the tumor results from ischemia. It will
be shown, in addition, that TNF-induced hemorrhagic necrosis is reduced, and
complete regression of the outer ring of living tumor tissue fails to occur, if the
host is made incapable ofgenerating an antitumor immune response. Moreover,
in all cases, almost lethal quantities of TNF were required to cause tumor
regression in immunocompetent mice.
Materials and Methods
Mice.
￿
A/Tru and AB6F1 (A X C57BL/6) female mice were used at 12 wk of age.
They were supplied by the Trudeau Institute Animal Breeding Facility, and were free of
common viral pathogens, as evidenced by the results of routine screening provided by the
Diagnostic Testing Service of Microbiological Associates, Bethesda, MD.
Tumors.
￿
The SA1 spindle cell sarcoma syngeneic in A/J mice was obtained some years
ago from The Jackson Laboratory, Bar Harbor, ME. It was grown as an ascites in A/Tru
mice, harvested in PBS, suspended in Fishers' medium (Gibco Laboratories, Grand Island,
NY) containing 10% DMSO and 20% FCS, and stored in small vials over liquid nitrogen
to serve as stock tumor. Experiments were performed in semisyngeneic AB6F, mice
because they were more plentiful and less expensive than the parental strains. There was
no evidence of hybrid resistance against the SA1 sarcoma. Before each experiment the
tumor was grown as an ascites intraperitoneally in AB6F, mice, harvested and washed in
PBS, and resusPended in PBS for implantation. Tumors were initiated by intradermal
injection of 10 tumor cells in the midventral region. Tumor growth was monitored
against time by measuring changes in the mean of two perpendicular diameters.
In Vitro Cytotoxic Assay for rTNF and TNS.
￿
A modified assay based on the procedure
described by Wang et al. (6) was used. Briefly, 1 .5 X 10' murine L929B cells in 100 JAI of
Eagle's MEM (Microbiological Associates, Walkersville, MD) containing 5% FCS and 100
U/ml of penicillin and 100 ug/ml streptomycin, were placed in individual wells of 96-well
microtiter plates, and incubated overnight at 37°C in a 5% C02 humidified incubator.
Sequential twofold dilutions of the rTNF solution or TNS were made in the above
medium containing 2 wg/ml of actinomycin D (Calbiochem-Behring Corp., LaJolla, CA),
and 100 jul ofeach dilution was added to replicate wells of microtest plates seeded the day
before with L929B cells. After 24 h of incubation, cytotoxicity was scored microscopically.
The cytotoxicity titer (U/ml) is defined as the highest dilution of the test material causing
50% or more destruction of the monolayer of L929B cells. To assess the relative
sensitivities of the L929B assay cells at different times an internal rTNF laboratory
standard was included in all assays. All given TNF titers (U/ml) have been corrected to
this standard preparation .
rTNF and TNS.
￿
Murine rTNF was produced in E. coli and purified (sp act 1 .37 X 108HAVELL ET AL.
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U/mg protein; <10 ng endotoxin/mg protein) as described previously (7). SDS-PAGE
showed that the purified preparation consisted of a single band corresponding to a mol
wt of 17 X 10'. This rTNF was generously supplied by Dr. Jan Tavernier (Ghent,
Belgium). TNS was prepared from the blood of mice that were injected intravenously 2
h earlier with 50 Ecg ofSalmonella enteritidisendotoxin (batch 3105-25, Difco Laboratories,
Detroit, MI). The mice had been injected intravenously 2 wk earlier with 1 mg of
formalin-killed P. acnes (Trudeau Institute), according to the standard procedure for
priming mice for endotoxin-induced TNF production (9).
Anti-rTNFAntibody.
￿
Specific neutralizing antibodies to pure murine rTNF were raised
in rabbits according to previously reported procedures (15). Initially, rabbits received a
total of 2 ml of an rTNF (10' U)/adjuvant mixture at multiple subcutaneous sites. The
first two biweekly immunizations were done with CFA, and all subsequent booster
immunizations were carried out with IFA. Immune sera were collected, heat inactivated
at 56°C for 30 min, and the IgG was purified and concentrated by three cycles of
(NH4)2SO4 precipitation (33% saturation), exhaustively dialyzed, and then sterilized by
filtration. 1 ml of the resulting IgG preparation was capable of neutralizing 3 X 106 TNF
units.
Quantitation of the TNF-induced TumorHemorrhagic Reaction.
￿
The TNF-induced intra-
tumor hemorrhaging was quantified by measuring the intratumor extravasation of "Cr-
labeled syngeneic red cellsagainst time. To prepare "Cr-labeled red cells, syngeneic mice
were bled by cardiac puncture into a syringe containing a solution of citric acid-dextrose
solution. The red cells were pelleted by centrifugation and washed three times in RPMI
1640 medium (Gibco Laboratories). To each 0.5 ml of packed red cellswas added 0.5 ml
of RPMI 1640 medium containing 100 EiCi of Nat "CrO, having a sp act of 250-500
mCi/mg (Amersham Corp., Arlington Heights, IL). The RBCs were suspended and
incubated for 1 h at 37 ° C, after which they were washed three times in RPMI 1640, and
resuspended in 2 ml of PBS for intravenous infusion. Each mouse was infused with 0.2
ml of the red cell suspension. This resulted in the labeling of ^-1 in 20 circulating red
cells. The mice were used in TNF experiments not earlier than 30 min after red cell
infusion. To measure TNF-induced intratumor hemorrhaging, mice were injected intra-
venously with rTNF or TNS, and at 5 min, and 1, 2, 4, and 6 h later, three to four mice
were bled by cardiac puncture, killed by cervical dislocation, and their tumors were
excised. Each tumor was placed in a glass vial and its content of "Cr was determined with
a Rack Gamma 11 Counter (LKB Instruments, Inc., Gaithersburg, MD). The results are
given as total counts per minute per tumor. The reaction was followed for only 4-6 h,
because the results of a study in progress (Havell, E. A., and R. J. North, submitted for
publication) show that extravasation of red cells does not continue beyond this time.
T Cell-deficient (TXB) Mice.
￿
Mice were made T cell deficient by thymectomy at 6 wk
of age followed 1 wk later by exposure to 1,000 rad of -y-radiation from a "'Cs source at
a midphantom dose rate of 30 rad/min. Immediately after irradiation, the mice were
infused with 2 X 106 syngeneic bone marrow cells, and used in experiments 6 wk or more
later.
Results
In Vitro Toxicity of rTNF and TNS for SA1 Tumor Cells and L929B Cells.
Although TNF was originally defined in terms of its ability to cause necrosis of
established tumors in vivo (1), it is currently being studied in most laboratories
in terms of its in vitro toxicity for neoplastic cells. Consequently, different
preparations of TNF are compared in terms of their in vitro cytotoxic activity.
Therefore, before investigating the therapeutic action of the rTNF and TNS
preparations in this laboratory against an established SA 1 sarcoma, it was
necessary to determine their cytotoxicity for L929B cells in vitro. It was also
necessary to determine whether they were capable of killing cells of the SA 1
sarcoma in vitro.1070 ANTITUMOR FUNCTION OF TUMOR NECROSIS FACTOR
TABLE I
In Vitro Cytotoxic Activities ofMurine Tumor Necrotizing Serum
(TNS) and Recombinant Murine Tumor Necrosis Factor (rMuTNF)
* 1 U of cytotoxic activity is the concentration of test preparation that
causes 50% destruction of a given cell type, and the titer of cytotoxic
activity (U/ml) is the reciprocal of the highest twofold dilution of the
preparation that causes >-50% cell destruction.
$ Allcellswere preseeded 1 dbefore theaddition of thegivenpreparation.
Actinomycin Dwasaddedto afinalconcentration of 1 wg/ml along with
the test preparation to preseeded cultures.
TABLE II
Specific Activities ofTNS and rTNF
Table I shows the toxicity ofthe rTNF and TNS preparations under study in
this laboratory for SA1 cells, L929B cells, and diploid AB6F, embryonic fibro-
blasts. Both preparations were highly toxic for SA1 cells, as well as for L929B
cells, but showed no cytotoxicity at all for embryonic fibroblasts. In keeping with
the general finding of others, treatment of L929B cells with actinomycin D
increased their sensitivity to rTNF and TNS by 500-1,000-fold. The rTNF
proved 200-800 times more active than TNS (U/ml) on the cells that were
susceptible. In Table II are given the specific activities of the pure rTNF and
TNS, based on their cytotoxic activities on actinomycin D-treated L929B cells.
The specific activity of the rTNF was 4 X 10' times greater than that of the
TNS.
rTNF and TNS Cause Regression of the SA1 Sarcoma But Only When Given at
Near Lethal Doses. Figs. 1 and 2 show the results ofattempts to cause complete
regression ofa 9-d SA1 sarcoma with intravenous injection ofdecreasing twofold
dilutions of rTNF and TNS, respectively, starting at 106 U of rTNF and 4 X
105 U ofTNS. It can be seen in the case ofrTNF that 106 U killed all mice; 5
X 105 U killed three of five, with the tumor in one of the survivors undergoing
complete regression; 2.5 X 105 was not lethal for any mice, but tumor regression
occurred in only three of five mice. The therapeutic effect of lower doses of
rTNF was even less impressive. It should be mentioned in regard to these
Cytotoxic activity
Sample on actinomycin protein Specific activity
D-treated (U/mg protein)
L929B cells
U/ml mg/ml
rMuTNF 4.1 X 10' 0.3 1.37 x 108
TNS 2.1 x 105 62.5 3.40 x 10'
Cells
Cytotoxicity
TNS
titer*
rMuTNF
L929B cells + actinomycin D$ 2.1 x 105 4.1 x 10'
L929B cells 3.2 x 102 6.4 x 104
SA-1 sarcoma 1 .0 x 105 8.2 x 105
Murine embryo fibroblasts <8 <8160-i
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FIGURE 1.
￿
Effect of intravenous injection of IV, 5 x 105, 2.5 x 105, or 1.25 x 105 U of
rTNF on growth of theSA1 sarcoma growing from an intradermal implant. The rTNF was
injected on day 9 of tumor growth. In this experiment the most therapeutic dose of rTNF
was 2.5 x 105 U, in that it caused complete regression of the tumor in three of five mice.
Higher doses were too toxic, whereas lower doses failed to cause tumor regression. All doses
tested were capable of causing hemorrhagic necrosis of >75% (+++) or 50% (++) of the
center of thetumor.
findings that the half-life of intravenously infused rTNF was determined to be
7-8 min, which is in agreement with the findings of Buetler and Cerami (3).
In the case ofTNS (Fig. 2), the most therapeutic dose was 105 U, which was
highly toxic but not lethal, and caused regression of tumors in five of five mice .
In other experiments, however, this dose of TNS killed a significant proportion
ofmice, and higher doses were more lethal .
Inall oftheabove experiments, tumors were examined24 h aftergiving rTNF
or TNS to subjectively assess the degree of central hemorrhagic necrosis. In
general, complete tumor regression was preceded by extensive hemorrhagic
necrosis involving >75% of the tumor (scored as +++). Smaller degrees of
hemorrhagic necrosis (scored as ++) resulting from lower doses of rTNF and
TNS left wider rims of living tumor tissue which, more often than not, did not
undergo complete regression.
Mice that died from the toxic effects of rTNF and TNS did so before 24 h.
However, those that survived therapeutic doses showed symptoms of extreme
toxicity, including hypothermia, lethargy, piloerection, and severe diarrhea.
The Effect of rTNF Was no Greater against Smaller Tumors or when Injected
Intratumorally. The foregoing experiments tested the ability ofrTNF and TNS
given intravenously to cause a regression ofa relatively large (8-9-mm diameter)
9-d tumor. A 9-d SA1 sarcoma was chosen because previous studies had shown1072
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FIGURE 2.
￿
Thesame experiment as shown in Fig. 1, except that TNSwasused. TNSproved
more reliable than rTNF at causing regression in that it was capable, in adose of 105 cytotoxic
units, of routinely causing regression of the SA1 sarcoma in five of five mice. Higher doses
were lethal, andlowerdoseswere less therapeutic. AlldosesofTNS tested caused hemorrhagic
necrosis that involved >75% (+++), or >50% (++) of the tumor'scenter.
(12, 13) that the tumor was most susceptible to endotoxin-induced regression at
this stage of its growth. The possibility existed, however, that tumor regression
could be achieved with less toxic amounts of rTNF or TNS if the tumor was
smaller at the time of treatment. It also seemed possible that more impressive
therapeutic results would be obtained if the agents were injected directly into
the tumor, rather than intravenously. It can be seen in Fig. 3 that neither
possibility turned out to be true, in that a dose that was partially therapeutic
against a 9-d tumor when given intravenously, was even less therapeutic against
a 3-d tumor. Again, giving this same dose of rTNF intralesionally did not
improve its therapeutic action against a 9-d or 3-d tumor. If anything, rTNF
tended to be less therapeutic when given intralesionally.
TNF-induced Tumor RegressionRequires that the Host be Immunocompetent.
￿
TNF
is supposed to be the molecular mediator of tumor hemorrhagic necrosis and
regression caused by parenteral injection of bacterial endotoxin. However,
endotoxin-induced regression of the SA 1 sarcoma is dependent on an underlying
antitumor immune response (12-14). It was anticipated, therefore, that rTNF-
induced and TNS-induced regression o£ the SA1 sarcoma also would require
that the host be capable of generating an antitumor immune response. This was
tested by determining whether rTNF or TNS could cause regression of the SA1
growing in TXB mice. The results in Figs. 4 and 5 show that, whereas a dose of
2.5 x 105 U of rTNF or 105 U of TNS caused either partial or complete
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Evidence that 105 or 2.5 x 105U ofrTNF was notsignificantly more therapeutic
when injected intratumorally than when injected intravenously. Nor was it more therapeutic
against a 3-d than a 9-d tumor, as judged by complete tumor regression. In this experiment,
higher doses ofrTNF were lethal for allmice.
regression ofa 9-d SA1 in immunocompetent mice, respectively, neither prepa-
ration caused regression of the tumor growing in TXB mice. It will be noted
that although rTNF caused complete regression ofthe tumor in only two offive
immunocompetent mice, it nevertheless caused appreciable regression of the
tumor in the remaining three mice. The temporary briefcessation ofgrowth of
tumors inall TXB mice treated with TNS wasthe result ofa central hemorrhagic
reaction.
Quantitation of the rTNF-induced Hemorrhagic Reaction by Measuring Intratumor
Extravasation of "Cr-labeled Red Cells. The therapeutic action of rTNF and
TNS against established tumors in vivo is subjectively assessed for the most part
in terms of the extensiveness of central hemorrhagic necrosis. On the other
hand, complete regression of the tumor is not commonly measured because it
rarely occurs. The same can be said for assessing the therapeutic action of
endotoxin, which also commonly causes hemorrhagic necrosis, but rarely com-
plete tumor regression. According to an elegant study performed by Algire et
al. 40 years ago (16), tumor hemorrhagic necrosis results from the destruction
of most of the tumor's vasculature, rather than from a direct toxic action of
endotoxin on tumor cells.
A functional collapse of the tumor's vasculature is almost certainly the way
that rTNF and TNS causes central hemorrhagic necrosis of the SA1 sarcoma.
This is indicated by the appearance ofa 9-d SA1 sarcoma undergoing a hemor-
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Evidence that the ability of rTNF to cause tumor regression depends on host
immunocompetence. A dose of 2.5 x 105 U of rTNF caused either complete or partial
regression of the SA1 growing in immunocompetent mice (left), but not if it was growing in
T cell-deficient (TXB) mice (right).
rhagic reaction in response to injection of 2.5 x 105 U of rTNF, as shown in
Fig. 6. It can be seen that the overall darkening of most of the tumor, as seen
from the external side, was caused by multiple petechial hemorrhages in the
tumor's vascular bed, as seen from the internal side. It is obvious that it is the
tumor'svascular bedand tumortissue internal to itthat isconsequently destroyed
by the ischemia resulting from loss ofblood supply.
It was found that the intratumor hemorrhagec reaction shown in Fig. 6 could
be quantified by measuring the intratumor extravasation and accumulation of
"Cr-labeled syngeneic red cells infused 30 min earlier, as described under
Materials and Methods. The results ofone of several experiments are shown in
Fig. 7 where it can be seen that while tumors of control mice infused with "Cr-
labeled red cells contained an approximately constant level of "Cr over the 6-h
period ofthe assay, the tumors of mice given rTNF intravenously accumulated
a large quantity of"Crduring thesameperiod. Itwill be noted thatextravasation
of "Cr-labeled red cells did not begin until ^-1 h after giving rTNF, and that by
6 h the tumors of rTNF-treated mice contained ^-10 times more "Cr-labeled
red cells than control tumors. Extravasation of red cells did not increase signifi-
cantly after 6 h.
TNF-induced Intratumor Hemorrhaging Partly Depends on Host Immunocompe-
tence. It can be seen in Fig. 8 that the ability of 2.5 x 105 U ofrTNF to cause
intratumor extravasation of
51Cr-labeled syngeneic red cells was substantiallyE
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￿
The same experiment as shown in Fig. 4, but performed with TNS instead of
rTNF. Means of five mice per group .
reduced if the tumor was growing in TXB mice . Whereas 5`Cr accumulated
progressively for 6 h in the tumors of rTNF-treated immunocompetent mice, it
accumulated for only 2 h in the tumors of TXB mice . A similar result was
obtained when TNS was used, except that in this case the biggest difference was
seen 4 h after giving TNS. There can be no doubt, in view of these results, that
host immunocompetence is needed for full development of the TNF-induced
intratumor hemorrhagic reaction .
Neutralization of In Vitro Cytotoxicity and In Vivo Antitumor Function of rTNF
and TNS by an Anti-rTNF Antibody. For future analysis of the in vitro and in
vivo antitumor function of TNF, it was considered necessary to raise an anti-
rTNF neutralizing antibody . A neutralizing antibody was also considered a
necessary tool to determine whether endogenous TNF is the mediator molecule
responsible for hemorrhagic necrosisandregression of establishedtumors caused
by endotoxin and other agents, as is generally assumed (1, 9) . Therefore, a
monospecific, polyvalent anti-rTNF antiserum was raised in rabbits, according
to the description given under Materials and Methods.
Table III shows that the antiserum was highly efficient at neutralizing the in
vitro cytotoxicity of both rTNF and TNS for L929B cells . However, it was six
times less efficient at neutralizing TNS than rTNF, and 100 times less efficient
at neutralizing human rTNF . It was completely incapable, on the other hand, of
neutralizing the cytotoxicity of recombinant human lymphotoxin .
A preparation of purified anti-rTNF IgG was also highly efficient at blocking
the ability of rTNF and TNS to cause tumor hemorrhagic necrosis in vivo . It
can be seen in Fig. 9 that giving anti-rTNF IgG intravenously to tumor-bearing
mice 1 h before giving them 2 .5 x 105 U ofrTNF or 105 U of TNS completely
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FIGURE 6 .
￿
Tumorfrom a controlmouse (left) andfrom a mouse treated 6h earlier with 2.5
x 10' U of rTNF (right) photographed from external side (tofu) and internal side (bottom) .
Central darkeningof the treated tumor seen from the external side wascaused by numerous
hemorrhages in the tumor's vascular bed . A small central necrotic core was already present at
thetime of treatment .N
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￿
Quantitation of the rTNF-
inducedhemorrhagic reaction shown in
Fig. 6, as determined by measuring in-
tratumor extravasation of "Cr-labeled
syngeneicred cells infused intravenously
30 min before giving 2.5 X 105 U of
rTNF. Means of four tumors per group
pertime point.
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FIGURE 8.
￿
Evidence that the rTNF-induced intratumor hemorrhagic reaction, as measured
by intratumor extravasationof "Cr-labeled redcells is partly dependenton host immunocom-
petence. Red cell extravasation continuedfor at leasta 6-h period in rTNF-treated immuno-
competentmice (left), butforonly 2 h in TXB mice (right). Means offour mice pergroup per
time point.1078
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TABLE III
Neutralization ofthe Cytotoxic Activities of rTNF, TNS, and Other Cytotoxic
Factors by Rabbit Anti-rMuTNFSerum
Cytotoxic factor
rMuTNF
TNS
rHuTNF
Human lymphotoxin (natural)
Human lymphotoxin (recombinant)
* The rabbit anti-rMuTNF neutralizing titer is defined as the reciprocal of the
highest dilution of the antiserum, which when reacted with an equal volume
of test sample containing 20 cytotoxic units/ml, neutralizes 50% ofthe activity
on actinomycin D-treated L929B murine fibroblasts.
This rMuTNF served as immunogen. Rabbit serum obtained before immuni-
zation possessed no anti-rMuTNF neutralizing activity (<16).
$ Serum collected from P. acnes-primed mice 2 h after the intravenous infusion
of 50 tug ofS. enteriditis endotoxin.
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FIGURE 9.
￿
Evidence that anti-rTNF antibody given intravenously in a dose of 3.2 x 10"
neutralizinj units was capable of completely preventing the ability of 2.5 x 105 U of rTNF
(left), or 10 U of TNS (right) to cause intratumor hemorrhaging, as measured by intratumor
extravasation of "Cr-labeled red cells. Mean counts pertumor of four tumors pergroup.
1
6
0
0
blocked the development of the tumor hemorrhagic reaction, as measured by
intratumor extravasation and accumulation of "Cr-labeled red cells. This result
is shown visually in Fig. 10, where it can be seen that anti-rTNF IgG completely
inhibited theability ofrTNF to cause hemorrhaging in the tumor's vascular bed.
Not surprisingly, therefore, the same 1-h pretreatment with anti-rTNF com-
Source
Neutralizing
titer*
U/ml
Biogent/Fiers$ 40,141
Trudeau/Northl 6,554
Cetus/Lin 410
RPMI/Sulkowski <26
Genentech/Shepard <26HAVELL ET AL.
FIGURE 10 .
￿
Appearance of a 9-d control tumor (top), a tumor undergoing a hemorrhagic
reaction in response torTNF given6 h earlier (middle), anda tumor in which a rTNF-induced
hemorrhagic reaction wasblocked by treating the host with anti-rTNFantibody 30 min before
giving rTNF (bottom). The left panel shows tumors photographed from the external side, and
the right panel showsthesame tumors photographed from the internal side.
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FIGURE 11 .
￿
Evidence that pretreatment of mice with 3.2 x 10" neutralizing units of anti-
rTNF antibody completely inhibited the ability of 2.5 x 105 U of rTNF (left), and 105 U of
TNS (right) to cause regression of the SAl sarcoma. The anti-rTNF was given 1 h before
rTNF on day 9 of tumor growth. Infusion of the same quantity of control IgG was without
effect. Meansof five mice pergroup.
pletely inhibited the ability of therapeutic doses of rTNF and TNS to cause
complete regression of a 9-d SA1 sarcoma (Fig. 11) . It should be mentioned,
moreover, that treatment with anti-rTNF IgG protected the tumor-bearing mice
from the toxic effects of rTNF and TNS, in that antibody-treated mice showed
no signs of lethargy, hypothermia, or diarrhea.
Discussion
The results of this study with an immunogenic tumor that is highly susceptible
to endotoxin therapy (12, 13) show that murine rTNF is not an impressive
antitumor agent when used as a single agent in mice, in that it cannot be relied
on to cause complete regression of this tumor in all mice, even when given in
highly toxic, near lethal doses. Natural TNF contained in TNS seems more
therapeutic, but the doses needed to cause tumor regression are also extremely
toxic. However, in the case of TNS, the participation of other monokines cannot
be ruled out. Multiple subtoxic doses of rTNF or TNS were no more therapeutic
than single toxicdoses (North, R. J., and E. A. Havell, manuscriptin preparation).
In our experience, therefore, rTNF is less therapeutic against the SA 1 sarcoma
than endotoxin itself (14, 17), even though TNF is supposed to mediate the
therapeutic effects of endotoxin (1, 9). It is also apparent (12-14, 17) that
parenterally injected endotoxin routinely causes complete regression of the SA 1
sarcoma with much less severe symptoms of toxicity than reported here for TNF.
The need for highly toxic doses of TNF to cause regression of an endotoxin-
susceptible tumor is in agreement with the recent findings of Bloksma andHAVELL ET AL.
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Hofhuis (18)and of Palladino et al . (19), who investigated the therapeutic efficacy
of human rTNF against the Meth A fibrosarcoma . These authors were not
impressed with the ability ofrTNF to cause regression of this tumor, in that they
found that the incidence of complete regressions in response to highly toxic
doses of rTNF was quite low. Indeed, it is apparent that in spite of the current
extensive interest in the cytotoxic function ofrTNF, very few published descrip-
tions exist of rTNF-induced regression of established tumors. Instead, the in
vivo antitumor function ofTNF is measured in terms of its ability to cause tumor
hemorrhagic necrosis . In other words, as a single agent TNF would have to be
considered to be of limited therapeutic value, ifjudged by its ability to cause
complete tumor regression .
It was shown in the present study, moreover, that the therapeutic efficacy of
murine rTNF could not be improved on by testing it against smaller tumors . On
the contrary, a 3-d (4-5-mm diameter) SA1 sarcoma was less susceptible to a 2 .5
x 105U dose ofrTNF than a 9-d (8-9-mm diameter) SA1, regardless ofwhether
rTNF was injected intravenously or directly into the tumor . With regard to
tumor size, it has been known for many years (10, 11) that parenterally injected
endotoxin is therapeutic only against tumors above a certain critical size . This
must surely be related to the reason why the Meth A fibrosarcoma invariably is
allowed to grow for 6-7 d before attempts are made to cause it to undergo
regression with TNS (1, 9) or rTNF (18, 19) .
One possible reason why rTNF is active only against well-established tumors
might be that a therapeutic effect requires that the host possess an underlying
mechanism of antitumor immunity, the generation ofwhich is not induced until
the tumor grows large enough to supply an adequate quantity of antigen .
Evidence that this is the case with endotoxin-induced tumor regression is supplied
in publications from this laboratory (14, 17), which show that until the host has
generated an adequate level of concomitant antitumor immunity, endotoxin is
ineffective in causing regression of the SA 1 sarcoma. In addition, these publica-
tions show that endotoxin fails to cause regression of the SA 1 sarcoma growing
in a TXB host, but does so if the host is supplied with L3T4''-sensitized T cells
from a concomitantly immune donor . Because it was shown here that neither
rTNF nor TNS is capable of causing regression of the SA1 sarcoma growing in
TXB mice, it seems reasonable to conclude that regression of thistumorby these
agents is alsodependent on an adequate level of underlying antitumor immunity .
This argues against the notion that TNF causes tumor regression by directly
killing cells of the tumor . Other evidence against direct cytotoxic destruction of
tumor cells by TNF in vivo is seen in the publications of others (18, 19) showing
that tumor cells that are resistant to the cytotoxic action of TNF in vitro
nevertheless form tumors that undergo hemorrhagic necrosis and occasional
regression in response toTNF in vivo.
Again, it was established here that the ability of TNF to cause tumor hemor-
rhagic necrosis, as opposed to tumor regression, is also partly dependent on host
immunocompetence. The results show that, whereas rTNF-induced intratumor
extravasation of "Cr-labeled red cells progressed for 6 h in tumors growing in
immunocompetent mice, it progressed for only 2 h in tumors growing in TXB
mice . This indicates that the TNF-induced tumor hemorrhagic reaction consists1082
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ofan initial immunologically independent phase, and a subsequent immunolog-
ically dependent phase. The meaning of this is unknown.
However, the therapeutic meaning of TNF-induced hemorrhagic necrosis as
a whole seems obvious. It almost certainly is responsible for rapid destruction of
most of the center of the tumor by ischemia, thereby leaving a greatly reduced
tumorburden for the host's immunologic defenses to cope with. Examination of
the SA1 sarcoma undergoing a TNF-induced hemorrhagic reaction revealed
that the rapid progressive darkening of most of the tumor as seen from its
external side several hours after giving rTNF intravenously is caused by numer-
ous petechial hemorrhages in the tumor's vascular bed. This intratumor hem-
orrhaging signifies irreversible damage to the tumor's vasculature and results
over the next 24 h in death and necrosis of most of the tumor's center. These
observations agree, therefore, with descriptions of tumor hemorrhagic necrosis
caused by endotoxin, as published by Algire et al. (16) more than 40 years ago.
These authors concluded that tumor necrosis is caused by a loss ofblood supply
to the tumor resulting from a functional collapse of most of the tumor's vascu-
lature. However, they observed, in addition, that in almost all cases the outer
rim ofthe tumor and the blood vessels therein survivethe hemorrhagic reaction,
and are capable ofrapid regrowth. Consequently, the tumor rapidlyreestablishes
itself unless other mechanisms are brought into play to destroy tumor tissue
surviving the hemorrhagic reaction. According to results obtained with rTNF
and TNS presented here, and the results obtained with endotoxin published
elsewhere (14, 17), complete regression of the outer rim of tumor tissue that
survives the initial hemorrhagic reaction requires that the host be capable of
generatingandexpressing anadequatelevel ofconcomitantantitumorimmunity.
Presumably, the greater the extent of hemorrhagic necrosis, the smaller the
amount of surviving living tumor tissue that needs to be destroyed by host
immunity, and the more likely it is that complete tumor regression will ensue.
This schemeofTNF-induced tumor regression impliesthat forTNF toinitiate
a therapeutic effect, the tumor needs to be adequately vascularized. It also
implies that tumor blood vessels are more susceptible to TNF than other blood
vessels. It has been demonstrated in this connection, that TNF can directly affect
the physiology ofvascular endothelial cells in vitro (20-22) and is cytotoxic for
these cells under certain conditions ifpresent in adequate concentration (21). It
seems obvious that the vasculatureofthe tumor is more susceptible to a sublethal
dose of TNF than the vasculature of normal tissues, because it is only in the
tumor that hemorrhaging is noticeable. We failed to find any macroscopic
evidence of hemorrhaging in the viscera of tumor-bearing mice treated with a
therapeutic dose of rTNF or TNS. It is known, in keeping with this idea, that
the vasculature of tumors is structurally abnormal (reviewed in reference 23),
and this implies underlying physiological defects. Presumably, however, the
extreme outer region of a tumor's vasculature is less abnormal, because this
escapes destruction by the TNF-induced hemorrhagic reaction. Itis even possible
that differences among tumors in their response to TNF therapy might be a
reflection of differences in the degree of abnormality of the endothelial cells of
their blood vessels.
As shown by Tracy et al. (24), however, very high, uniformally lethal doses ofHAVELL ET AL .
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TNF (also called cachectin) cause localized hemorrhaging and ischemic destruc-
tion in the tissues at large, including those of the lungs and intestines. Additional
symptoms of TNF/cachectin-induced physiological decompensation include hy-
potension, hemoconcentration, intravascular coagulation, and metabolic acidosis .
Unfortunately, to cause extensive hemorrhagic necrosis and/or regression of the
SA1 sarcoma, it was necessary to give the host doses of rTNF or TNS capable
of causing these same symptoms to some degree . Others have experienced the
same problem in attempting to cause regression of the Meth A fibrosarcoma
with rTNF (18, 19) .
On the other hand, and in keeping with the findings of Buetler et al . (25),
these toxic symptoms failed to manifest themselves in SA 1 sarcoma-bearing mice
that were given anti-rTNF antibody intravenously before being given TNF .
However, neutralization of toxicity went hand in hand with neutralization of the
ability ofTNF to cause tumor hemorrhagic necrosis and regression . The ability
of this same antibody to inhibit endotoxin-induced hemorrhagic necrosis and
regression of the SA1 sarcoma will be dealt with in the paper that follows (26) .
Lastly, the results presented in Table III show that more (six times) anti-rTNF
antibody was required to neutralize the cytotoxic activity of natural TNF (TNS)
than was required to neutralize the immunogen (rTNF) . Obviously, a number
of possibilities could be offered to explain this . It is possible, for example, that
the antibody has more affinity for rTNF than for natural TNF . Alternatively,
natural TNF may be more therapeutically active than rTNF . With regard to the
later possibility, studies are underway to establish the amount of natural TNF
protein present in TNS, so that activities of the pure rTNF and natural TNF
can be compared on a molar basis .
Summary
The ability of murine recombinant tumor necrosis factor (rTNF) and natural
TNF in tumor-necrotizing serum (TNS) to cause regression of the SA1 sarcoma
was investigated . We found that to cause regression of a 9-d SAI sarcoma, near
lethal quantities of rTNF and TNS had to be given to the host . However, even
at these highly toxic doses, rTNF was not reliable at causing complete tumor
regression . On the other hand, both types of TNF were reliable at causing a
tumor hemorrhagic reaction that resulted in the destruction of >75% of the
tumor's center in 24 h . The TNF-induced hemorrhagic reaction involved the
development of numerous petechial hemorrhages in the tumor's vascular bed,
which apparently resulted from destruction of the tumor's blood vessels . It was
possible to follow the development of the hemorrhagic reaction against time
after giving rTNF or TNS by measuring the intratumor extravasation of 5 'Cr-
labeled syngeneic red cells . According to this method, TNF-induced intratumor
hemorrhaging was in progress within 1 h of giving TNF and continued for about
a 6-h period . However, the hemorrhagic reaction was greatly reduced and
complete regression of the rim of the living tumor tissue that survived hemor-
rhagic necrosis failed to occur, if SA 1 sarcoma was growing in T cell-deficient
(TXB) mice . This indicates that the TNF-induced hemorrhagic reaction is partly
dependent, and the tumor regression that follows is completely dependent on
host immunocompetence . This suggests in turn, that rTNF does not directly1084
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destroy SA1 tumor cells in vivo, even though it was shown that it can destroy
SA1 tumor cells in vitro. This interpretation is supported by the additional
findings that rTNF was no more therapeutic against a 3-d (3-mm) SA1 than
against a 9-d (8-mm) SA 1, and was no more therapeutic when injected directly
into the tumor than when injected intravenously. Lastly it was possible to
completely inhibit the ability of rTNF and TNS to cause tumor hemorrhagic
necrosis and regression by infusing the host with a monospecific, polyvalent anti-
rTNF antibody that neutralized the cytotoxic action of rTNF in vitro.
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